A phase II trial of trastuzumab, Neupogen [filgrastim], and vinorelbine investigating the effects on immune function and clinical outcomes in patients with metastatic breast cancer overexpressing HER-2/neu.
Phase of Trial: Phase II/III
Latest Information Update: 22 Jul 2018
At a glance
- Drugs Filgrastim; Granulocyte colony-stimulating factors; Trastuzumab; Vinorelbine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Oct 2011 Trial phase changed from II to II/III as reported by ClinicalTrials.gov.
- 11 Aug 2009 Actual number of patients (23) added as reported by ClinicalTrials.gov